FDA's approval of the first generic version of Copaxone for treating patients with relapsing forms of multiple sclerosis has industry insiders contemplating payer coverage strategies.
Read More
To some degree, antibiotic resistance is unavoidable, but the more antibiotics are used, the more opportunities bacteria have to evolve to defeat them. View the top 5
A recent study conducted by the Harvard School of Public Health's Department of Health Policy and Management explored the prevalence of "adverse tiering" in exchange plans. Find out more
